Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/Optometrymedical mutual - ohio Miebo Coverage Prior Auth | …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Miebo (perfluorohexyloctane) — Coverage Criteria for Dry Eye Disease

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for prior authorization, clinical criteria, and coverage determination for Miebo ophthalmic solution for treatment of signs and symptoms of dry eye disease in adults; affects prescribers and pharmacy benefit adjudication.

    Policy Summary
    Payermedical mutual - ohio
    PolicyMiebo (perfluorohexyloctane) — Coverage Criteria for Dry Eye Disease
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionObtain prior authorization and ensure prescription is by or in consultation with an ophthalmologist, optometrist, or rheumatologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum patient age for coverage
    1 yrinitial approval duration
    1 yrextended approval duration
    Schirmer/TBUT/osm/staindiagnostic tests accepted

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Miebo (perfluorohexyloctane)

    Dry Eye Disease, Initial Use

    Covered when ALL of the following are met:

    Initial use criteria: A. Patient is 18 years of age or older; AND B. Medication is prescribed by or in consultation with an ophthalmologist, optometrist, or rheumatologist; AND C. Provider has administered testing for one of the following homeostasis markers with corresponding results: a) Schirmer's test (< 5.5 mm wetting over 5 minutes) OR b) Non-invasive tear breakup time (< 10 s) OR c) Osmolarity (>= 308 mOsm/L in either eye or interocular difference > 8 mOsm/L) OR d) Ocular surface staining (> 5 corneal spots OR > 9 conjunctival spots OR lid margin >= 2 mm length and >= 25% width); AND D. If diagnosis is mild dry eye disease, patient has tried and failed preservative-free artificial tears.

    From Recommended Authorization Criteria

    Dry Eye Disease, Continuation of Therapy

    Covered when ALL of the following are met:

    Continuation criteria: A. Patient is 18 years of age or older; AND B. Medication is prescribed by or in consultation with an ophthalmologist, optometrist, or rheumatologist; AND C. Patient has had a beneficial response to therapy, including reduced eye irritation, dryness, red eyes, or burning.

    From Continuation of Therapy section

    Concomitant use of Miebo with ophthalmic cyclosporine products (Cequa, Restasis, Vevye), Tyrvaya (varenicline nasal solution), Tryptyr (acoltremon ophthalmic solution), or Xiidra (lifitegrast ophthalmic solution) is not recommended due to lack of data supporting combined use. Providers should avoid prescribing Miebo together with these agents unless new evidence becomes available that supports concomitant administration.

    Coverage is not recommended for indications or circumstances that are not specifically listed in the Recommended Authorization Criteria. Criteria will be updated as new published data become available; until then, requests outside the listed criteria should be denied or referred for further review.

    Use of Miebo for conditions with limited or preliminary evidence, or where potential safety concerns exist, is not recommended. The company may deny reimbursement when the drug is considered investigational, experimental, or not medically necessary for the requested indication. Providers must supply supporting documentation when requested to justify off-label or investigational uses.

    Diagnostic Criteria and Test Thresholds

    inv-06: Schirmer test wetting
    Schirmer test wetting threshold< 5.5 mm of wetting over 5 minutes
    Test purposeAssesses aqueous tear production to support DED diagnosis
    Use in criteriaOne accepted homeostasis marker for initial Miebo coverage
    inv-07: Non-invasive tear breakup time
    Non-invasive tear breakup time (NITBUT) threshold< 10 seconds
    Test purposeMeasures tear film stability to support DED diagnosis
    Use in criteria

    Prior Authorization, Prescriber & Documentation Requirements

    Prior Authorization

    Prior authorization and prescriber requirement

    Prior authorization is recommended for pharmacy benefit coverage of Miebo. Initial approval must be prescribed by or in consultation with a physician who specializes in the treated condition.

    Note

    Age and prescriber requirements for initial and continuation therapy

    Initial and continuation therapy require the patient to be 18 years or older and the medication to be prescribed by or in consultation with an ophthalmologist, optometrist, or rheumatologist; continuation also requires a beneficial response to therapy.

    • Initial: patient ≥ 18 years; prescribed by or in consultation with ophthalmologist, optometrist, or rheumatologist; required diagnostic testing per policy.
    • Continuation: patient ≥ 18 years; prescribed by or in consultation with ophthalmologist, optometrist, or rheumatologist; documented beneficial response (reduced irritation, dryness, redness, or burning).

    Background on Miebo and Dry Eye Disease

    Miebo (perfluorohexyloctane) is a semifluorinated alkane ophthalmic solution indicated for the treatment of signs and symptoms of dry eye disease (DED). The American Academy of Ophthalmology classifies DED as mild, moderate, or severe and recommends a stepwise progression of treatments; choice of therapy should reflect disease severity, clinical judgment, and patient preference.

    This policy provides prior authorization and clinical criteria for Miebo in adults. The product's safety and effectiveness have not been established in patients under 18 years of age, and coverage decisions follow the Recommended Authorization Criteria that require objective testing or documented treatment failure where applicable.

    Definitions

    inv-16: Miebo
    Product definitionMiebo (perfluorohexyloctane) ophthalmic solution, a semifluorinated alkane indicated for treatment of signs and symptoms of dry eye disease
    IndicationTreatment of signs and symptoms of dry eye disease (DED) in adults
    Safety/effectiveness noteSafety and effectiveness not established in pediatric patients < 18 years of age
    inv-17: Dry eye disease (DED)
    Definition of DEDDry eye disease (DED) is classified by the AAO as mild, moderate, or severe based on signs and symptoms
    Treatment organizationAAO recommends a four-step progression of treatments; therapies may be selected from any category based on provider judgment and patient preference
    Policy Summary
    Payermedical mutual - ohio
    PolicyMiebo (perfluorohexyloctane) — Coverage Criteria for Dry Eye Disease
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionObtain prior authorization and ensure prescription is by or in consultation with an ophthalmologist, optometrist, or rheumatologist.
    SourceLink
    On This Page
    Coverage Criteria for Miebo (perfluorohexyloctane)Diagnostic Criteria and Test ThresholdsPrior Authorization, Prescriber & Documentation RequirementsBackground on Miebo and Dry Eye DiseaseDefinitions
    One accepted homeostasis marker for initial Miebo coverage
    inv-08: Osmolarity
    Osmolarity threshold (either eye)>= 308 mOsm/L in either eye
    Interocular difference> 8 mOsm/L interocular difference also meets threshold
    Use in criteriaOne accepted homeostasis marker for initial Miebo coverage
    inv-09: Ocular surface staining
    Corneal staining threshold> 5 corneal spots
    Conjunctival staining threshold> 9 conjunctival spots
    Lid margin staining thresholdLid margin ≥ 2 mm length AND ≥ 25% width
    Step Therapy

    Step therapy for mild DED: trial of preservative‑free artificial tears

    For patients with mild dry eye disease, the patient must have tried and failed preservative‑free artificial tears before Miebo will be covered.

    • Step required only when diagnosis is mild DED as specified in the initial use criteria.
    Documentation Required

    Documentation must be provided on request

    Make available upon request additional documentation to support coverage determinations, including patient records, test results, and provider credentials; the Company may request other documentation as needed.

    • Documentation may include patient records, test results, and credentials of the provider ordering or performing the service.
    • The Company reserves the right to request additional documentation during coverage review.
    Denial Risk

    Denial risk triggers

    The Company may deny reimbursement when the drug or services were not medically necessary, were investigational/experimental, were outside the member's benefits, or when billing/practice patterns are inappropriate or excessive.

    • Denial may be issued for investigational or not medically necessary uses.
    • Denial may be issued for services not within scope of benefits or for inappropriate/excessive billing or practice patterns.
    Policy applicationTreatment severity (mild/moderate/severe) guides stepwise recommendations and requirements such as trial of preservative‑free artificial tears for mild DED prior to Miebo